196 results about "Auto immune" patented technology

The invention discloses an arabidopsis thaliana RK3 gene and application of S structural domain receptor kinase RK3 coded by the arabidopsis thaliana RK3 gene in improvement of plant disease resistance, and belongs to the technical field of plant genetic engineering. According to the application of the arabidopsis thaliana RK3 gene to improvement of plant disease resistance, the nucleotide sequence of the arabidopsis thaliana RK3 gene is shown as SEQ ID NO.1, the amino acid sequence of S structural domain receptor kinase RK3 coded by the arabidopsis thaliana RK3 gene is shown as SEQ ID NO.2, and further plants are selected from arabidopsis thaliana, oilseed rape, rice, tomatoes, potatoes, peanuts, soybeans, cotton, tobacco, cucumbers, watermelons and the like. The expression of the plant disease resistance comprises infection resistance to wild-type pseudomonas syringae, effector engineering strains thereof and botrytis cinerea. It is clear that the arabidopsis thaliana RK3 gene and the encoded protein thereof can remarkably enhance the infection resistance of plants to various pathogenic bacteria for the first time, disease prevention and control are achieved by activating the autoimmune system of the plants, and an effective path is provided for reducing chemical pesticide application and promoting agricultural green development.

The invention discloses a chimera for degrading a CARD structural domain protein aggregate and application of the chimera. The chimera is prepared from light-operated targeting protein and light-operated degradation protein, the light-operated targeting protein is sequentially connected by an MAVS CARD structural domain, a flexible connecting peptide and a photosensitive protein pMag; the light-controlled degradation protein is sequentially connected by a photosensitive protein nMag, a flexible connecting peptide and an RING structural domain of TRIM21. According to the application, a light-operated activated CARD-RING chimera is constructed, and when the CARTAC generates toxic and side effects or in cells with RIG-I / MDA5 signal channels abnormally activated, the activity of the CARTAC can be effectively controlled or autoimmune diseases caused by RIG-I / MDA5 abnormity can be inhibited.

The invention discloses a dental ulcer image recognition autoimmune disease blood index correlation analysis system, and relates to the technical field of medical informatics. Comprising a time sequence data acquisition module, a steady state baseline construction module, a cross-modal synchronous analysis module, a deviation degree calculation module, a disease risk judgment module and a risk early warning output module. The system constructs an individualized immune steady-state baseline by acquiring a dental ulcer image of a user and time sequence data of blood indexes related to autoimmunity; the image lesion dynamic evolution rate is used as a guide factor, time extrapolation is carried out on the blood indexes collected asynchronously, and synchronous predictive immune data are generated; by calculating the deviation degree of the prediction data and the steady state baseline, accurate and real-time judgment and early warning of the autoimmune disease risk are realized. According to the invention, the problem of evaluation delay caused by desynchrony of dental ulcer image and blood index acquisition time is effectively solved, and the timeliness and accuracy of health risk monitoring are improved.

Disclosed herein is a method of treating an individual afflicted with moderate to severe ulcerative colitis, the method comprising: administering a local inhibitor of interleukin-23 (IL-23) and tumor necrosis factor alpha (TNF-alpha) to an intestine of the individual.

The invention discloses TCN1 (Trancobalamin 1, cobalamin 1) and application of an inhibitor of the TCN1 in preparation of products for diagnosing and treating diseases of an autoimmune system. According to the invention, expression in psoriasis tissues is up-regulated and promoter DNA methylation is down-regulated into genes to screen TCN1 genes, an over-expression TCN1 HaCaT cell line is constructed, and it is verified that the over-expression TCN1 HaCaT cell line participates in keratinocyte proliferation and IL-17 activation as an autoantigen, can be used as a diagnostic marker and a therapeutic target of autoimmune skin diseases such as psoriasis and the like, and has broad application prospects. And a new direction is provided for mechanism research and treatment of autoimmune skin diseases such as psoriasis.

Described herein are LAG3 specific single domain antibodies and binding molecules comprising such single domain antibodies, as well as nucleic acids encoding the same. Also provided are nucleic acids (e.g., mRNA) encoding such single domain antibodies and binding molecules and delivery vehicles (e.g., lipid nanoparticles) formulated with said nucleic acids. The disclosure also features methods of using such antibodies, binding molecules, nucleic acids, and delivery vehicles formulated with said nucleic acids to treat various diseases such as inflammatory diseases, T cell driven autoimmune diseases, and cancer (e.g., solid tumors or hematological malignancies).

The application discloses an oral ulcer image recognition autoimmune disease blood index correlation analysis system and relates to the technical field of medical informatics. The system comprises a time series data acquisition module, a steady-state baseline construction module, a cross-modal synchronous analysis module, a deviation calculation module, a disease risk determination module and a risk warning output module. The system acquires the time series data of the oral ulcer image and the autoimmune related blood index of the user, and constructs an individualized immune steady-state baseline. The dynamic evolution rate of the image lesion is used as a guide factor to time extrapolate the non-synchronous collected blood index, generate synchronous predictive immune data, calculate the deviation of the predictive data and the steady-state baseline, and realize accurate and real-time determination and early warning of the autoimmune disease risk. The application effectively solves the evaluation delay problem caused by the asynchronous collection of the oral ulcer image and the blood index, and improves the timeliness and accuracy of health risk monitoring.

The present disclosure relates to collagen binding modification engineering of anti-inflammatory agents using collagen binding peptides (CBP) and vWF A3 to achieve targeted therapy of inflammatory diseases. Accordingly, embodiments of the present disclosure relate to compositions comprising an anti-inflammatory agent operably linked to an extracellular matrix (ECM) affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to serum proteins and / or ECM affinity peptides. Other aspects of the present disclosure relate to methods for treating an autoimmune or inflammatory disorder in a subject comprising administering to the subject a composition of the present disclosure.

Use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or an isotopically labeled compound thereof in the preparation of a drug for preventing or treating neurodegenerative diseases, autoimmune and systemic inflammatory diseases, metabolic and cardiovascular diseases, respiratory diseases, ophthalmic diseases, or kidney diseases.

Provided herein are bispecific antibodies and antibody fragments that bind to both human TNFRSF25 and Α4Β7. Methods of treating or preventing diseases or disorders associated with inflammation and / or autoimmunity are provided, comprising administering to a patient in need thereof an effective amount of a human TNFRSF25- and Α4Β7-binding bispecific antibody.

The present invention relates to methods and compositions for the treatment of autoimmune diseases and of excessive hair shedding or hair loss in a subject or for promoting hair growth in a subject wherein the subject has an autoimmune hair loss disorder, such as alopecia areata. The methods and compositions comprise the administration of a janus kinase inhibitor, such as tofacitinib, wherein the inhibitor is predominantly absorbed through the oral mucosal routes such as the sublingual mucosa.

The present invention relates to antigen-binding proteins, related fragments thereof, for binding to CD80, and their use for treating various conditions such as inflammation and autoimmunity.

The invention discloses a structure-driven single cell transcriptomics immune cell annotation system and method, and the system comprises a data loading and preprocessing module which is used for loading a marker table and data after single cell clustering, and extracting the expression characteristic statistic of each cluster from the marker table and data to form a characteristic matrix; the basic structure annotation module is used for carrying out preliminary structure annotation on peripheral blood mononuclear cells and tissue samples; the tissue extension annotation module is used for completing structure extension and refinement under tissue expression drift on the basis of preliminary structure annotation according to a sample structure annotation requirement from peripheral tissues; and the structure dimension auxiliary annotation module is configured to integrate the dimension reduction coordinates and the adjacency graph information after being triggered, and perform spatial consistency verification and auxiliary correction on the low-confidence annotation result. According to the method, an automatic annotation function with high accuracy, strong controllability and good interpretability can be realized, and the method has high interpretability and robustness.

The present invention relates to a DcR3 variant, DNA encoding the DcR3 variant, a vector containing the DNA, a transformant obtained by introducing the vector, a method for producing a variant using the transformant, and a prophylactic or therapeutic agent for an autoimmune disease, an inflammatory disease or an allergic disease comprising the variant as an active ingredient. The present invention relates to a DcR3 variant having binding activity (preferably neutralizing activity) against a ligand of DcR3 while showing reduced production of aggregates and / or improved in vivo kinetics compared to wild-type DcR3 when prepared with a mammalian-derived cell as a host, and provides a DcR3 variant comprising a portion of DcR3 and a portion of a TNF superfamily molecule.

Disclosed in the present invention are a PIM kinase inhibitor as shown in general formula II, a pharmaceutical composition thereof, a preparation method therefor and the use thereof in the preparation of a drug for preventing and / or treating indications related to a PIM signaling pathway. The compound of the present invention is an ideal PIM kinase inhibitor with a high activity, which can be used for treating and / or preventing diseases including autoimmune diseases and tumors, e.g., inflammatory bowel disease, hematologic malignancies such as acute myeloid leukemia, myelofibrosis and chronic lymphocytic leukemia, and solid tumors such as gastric cancer and prostate cancer.

Provided is a use of a recombinant fusion protein in the preparation of a drug for treating an autoimmune disease that can benefit from the reduction or elimination of CD20+B cells (for example, CD20+ B cell depletion therapy). The recombinant fusion protein comprises i) a CD47-binding peptide, and ii) an anti-CD20 antibody or an antigen-binding portion thereof, wherein the CD47-binding peptide comprises a first extracellular Ig-like domain (SIRPαD1) of signal regulatory protein α (SIRPα), and the anti-CD20 antibody or the antigen-binding portion thereof comprises a heavy chain variable region, a heavy chain constant region, a light chain variable region, and a light chain constant region. The heavy chain variable region comprises VH-CDR1, VH-CDR2, and VH-CDR3, and the light chain variable region comprises VL-CDR1, VL-CDR2, and VL-CDR3, wherein the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 respectively comprise amino acid sequences as shown in GYTFTSYN (SEQ ID NO: 1), IYPGNGDT (SEQ ID NO: 2), ARSTYYGGDWYFNV (SEQ ID NO: 3), SSVSY (SEQ ID NO: 4), ATS, and QQWTSNPPT (SEQ ID NO: 5). The heavy chain constant region has the binding capacity for an FcR or a complement system protein. The CD47-binding peptide is linked to the N-terminus of the heavy chain variable region or light chain variable region of the anti-CD20 antibody or the antigen-binding portion thereof.

The invention discloses a compound immunopotentiator and application thereof in prevention and control of aquatic diseases, and belongs to the technical field of aquaculture. The compound immunopotentiator is prepared by scientifically compounding eucommia ulmoides, astragalus membranaceus, curcumin, vitamin A, vitamin D3, vitamin E and vitamin K3. According to the compound immunopotentiator, through the synergistic effect of the Chinese herbal medicine extract and the compound vitamins, the autoimmunity of aquaculture animal bodies can be remarkably improved, the resistance of the aquaculture animal bodies to pathogenic microorganisms and bad environments is enhanced, the compound immunopotentiator further has a good pathogen removing effect, and damage of pathogens to the aquaculture animals can be effectively reduced. The compound immunopotentiator provided by the invention is used as a combination of a plant-derived drug and multivitamins, has no problems of environmental pollution and drug resistance, and is good in safety and effectiveness.

A genetically modified mesenchymal stem cell including an exogenous nucleic acid including a Klotho encoding region operably linked to a promoter or promoter / enhancer combination, wherein the genetically modified mesenchymal stem cell exhibits increased Klotho expression compared to an unmodified mesenchymal stem cell. Also disclosed are methods of treating a patient including administering a therapeutically effective number of the genetically modified mesenchymal stem cells to the patient. The methods of treatment include treating the patient for a neurodegenerative disease; cancer; organ fibrosis; renal disease; age-related changes of organs or organ systems; to slow, reverse and / or inhibit aging; arteriosclerosis; dementia; diabetes mellitus; erectile dysfunction; autoimmune diseases or autoimmune-related diseases; an inflammatory disease of the lung and sepsis.

The present invention pertains to the treatment of diseases associated with a dysregulated immune response such as auto immune disorders, inflammatory diseases or pathological immune responses as adverse effects of medical treatments. In particular the invention provides a combined use of inhibitors of Receptor-interacting serine / threonine-protein kinase (RIPK1) and inhibitors of Inhibitor of κB (IκB) Kinase (IKK) in subjects suffering from such disorders. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention.

Disclosed herein are tumor-associated antigen-specific binding polypeptides. These binding polypeptides may be incorporated into chimeric antigen receptors (CARs). Also disclosed herein are methods of using these binding polypeptides and / or CARs for the treatment of, for example, an immune and / or autoimmune disease or disorder. In some embodiments, CARs are capable of binding to CEA6 (CEACAM6), and / or a second ligand.

This invention belongs to the field of biomedical technology, specifically relating to the application of a functional lipid in the preparation of drugs for treating systemic lupus erythematosus (SLE). Specifically, the functional lipid MLnM exhibits significant therapeutic effects in a pristane-induced SLE mouse model, effectively alleviating SLE-related clinical symptoms, improving intestinal barrier function, reducing oxidative stress levels, regulating the balance of inflammatory cytokine secretion, and reducing systemic inflammatory responses by inhibiting the expression of immune cell migration-related genes. The discovery of MLnM provides a new direction for the treatment of SLE and other autoimmune diseases.

Disclosed herein are extracellular vesicles comprising an immunomodulatory component. Methods of producing the extracellular vesicles and methods of using the extracellular vesicles to treat cancer, GvHD, and autoimmune diseases are also provided.

The present application relates to a plurality of anhydrous crystal forms of N-(3-(6-amino-5-(2-(N-methacrylamido) ethyoxyl) pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, as well as compositions, methods of preparation and methods of use thereof. These crystalline forms are useful in the treatment of diseases and disorders that are typically ameliorated by inhibition of BTK. Such diseases and disorders may include inflammation and autoimmune disorders as well as lung and respiratory tract inflammation.

The present invention provides intravenous pharmaceutical compositions comprising engineered plant virus-based nanoparticles for the treatment or prevention of autoimmune conditions. The nanoparticles display immunodominant peptides that induce immune tolerance in a subject when administered intravenously. The invention further provides methods of manufacturing virus-based nanoparticles, including production in plant expression systems and optional viral inactivation, to render them suitable for therapeutic use in mammals. Also provided are methods of intravenous administration of the pharmaceutical compositions to a subject in need thereof for treating or preventing autoimmune conditions.

The invention relates to a polycyclic fused BTK degradation agent and application thereof in medicine, in particular to a compound shown in a general formula (I) or a stereoisomer, a tautomer, a solvate, a prodrug, a metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate and a preparation method thereof, and application of the compound in BTK related diseases such as tumors or autoimmune system diseases, such as tumors, autoimmune system diseases and the like. And preferably recurrent / refractory B-cell malignant tumors.

The invention provides a chimeric antigen receptor targeting CD19 and / or CD20 and application thereof, the chimeric antigen receptor comprises: an extracellular domain capable of binding to CD20 and / or CD19; the extracellular domain is connected with the amino acid sequence, the transmembrane domain is connected with the extracellular domain, the intracellular domain is connected with the transmembrane domain, and the intracellular domain is selected from all amino acid sequences or partial amino acid sequences of at least one of the following proteins: 2B4, DAP10 and CD3zeta. The chimeric antigen receptor disclosed by the invention has double-target recognition capability and can be simultaneously combined with CD19 and CD20, so that the chimeric antigen receptor can cover a full differentiation stage of pathogenic B cells in autoimmune diseases and block a production path of an autoantibody from a source of a pathological mechanism; meanwhile, based on the inherent regulation and control capability of NK cells on lesion T cells, pathogenic T cells are removed, and the removal effect of B cells is cooperated, so that bidirectional blocking treatment on autoimmune pathology is realized.

The present application relates to the field of medicinal chemistry and the field of autoimmune disease treatment. The present application provides a compound and a use thereof in treatment of NMDAR-related diseases.

Provided herein are antibodies, and antibody fragments thereof, that bind human survivin. Also provided herein are isolated nucleic acids, expression vectors, host cells, pharmaceutical compositions, and kits that relate to the antibodies and antibody fragments. Finally, methods of treating survivin-mediated disorders are also provided, such as various autoimmune disorders and cancer.